Dmitry Balyasny Balyasny Asset Management
Dmitry Balyasny is the founder of Balyasny Asset Management, a major multi-strategy and multi-manager hedge fund platform. The firm allocates capital across fundamental equities, macro, quant, and other teams under a central risk framework. Balyasny’s platform is often cited alongside other leading pod-shop multi-strategy firms.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SPCX
SpaceX
SPCX
|
+$577M |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$538M |
| 3 |
iShares Core S&P 500 ETF
IVV
|
+$517M |
| 4 |
Texas Instruments
TXN
|
+$413M |
| 5 |
Roku
ROKU
|
+$356M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
HOLX
Hologic
HOLX
|
+$357M |
| 2 |
Meta Platforms (Facebook)
META
|
+$326M |
| 3 |
Johnson Controls International
JCI
|
+$303M |
| 4 |
Applied Materials
AMAT
|
+$285M |
| 5 |
CTRA
Coterra Energy
CTRA
|
+$285M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 12.69% |
| 2 | Industrials | 9.96% |
| 3 | Consumer Discretionary | 8.03% |
| 4 | Healthcare | 7.46% |
| 5 | Financials | 6.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
951
CALL
Duolingo
DUOL
$6.84B
| $11.5M | 0.01% |
100,000
| – | – |
|
952
PUT
Cameco
CCJ
$44.6B
| $11.4M | 0.01% |
112,300
+31,700
| +39% | +$3.55M |
|
953
CALL
SLB Ltd
SLB
$79.9B
| $11.4M | 0.01% |
245,500
+82,200
| +50% | +$4.41M |
|
954
CALL
Ford
F
$57.5B
| $11.4M | 0.01% |
817,100
+39,800
| +5% | +$537K |
|
955
Perspective Therapeutics
CATX
$377M
| $11.3M | 0.01% |
3,320,224
+325,764
| +11% | +$1.23M |
|
956
Chevron
CVX
$403B
| $11.3M | 0.01% |
68,139
-27,137
| -28% | -$5.05M |
|
957
CALL
United Airlines
UAL
$36.7B
| $11.3M | 0.01% |
83,000
+2,700
| +3% | +$280K |
|
958
CAMP4 Therapeutics
CAMP
$281M
| $11.3M | 0.01% |
2,575,724
-56,713
| -2% | -$245K |
|
959
Global X Silver Miners ETF NEW
SIL
$5.37B
| $11.3M | 0.01% |
+145,268
| New | +$13M |
|
960
Lexeo Therapeutics
LXEO
$400M
| $11.2M | 0.01% |
2,412,742
+823,157
| +52% | +$4.45M |
|
961
Merit Medical Systems
MMSI
$5.42B
| $11.2M | 0.01% |
161,785
-158,874
| -50% | -$10.5M |
|
962
Bright Horizons
BFAM
$3.54B
| $11.2M | 0.01% |
+157,594
| New | +$11.4M |
|
963
Bentley Systems
BSY
$11.2B
| $11.1M | 0.01% |
372,440
+155,158
| +71% | +$5.05M |
|
964
CALL
Denali Therapeutics
DNLI
$3.98B
| $11.1M | 0.01% |
+432,800
| New | +$8.89M |
|
965
IDEAYA Biosciences
IDYA
$3.83B
| $11.1M | 0.01% |
297,565
+89,220
| +43% | +$2.73M |
|
966
ConocoPhillips
COP
$162B
| $11.1M | 0.01% |
106,431
+70,230
| +194% | +$8.32M |
|
967
BOK Financial
BOKF
$8.54B
| $11M | 0.01% |
79,409
+32,770
| +70% | +$4.33M |
|
|
PLGO
968
Pelagos Insurance Capital
PLGO
$2.06B
| $11M | 0.01% |
452,008
-37,640
| -8% | -$819K |
|
969
CALL
Erasca
ERAS
$6.17B
| $11M | 0.01% |
+600,000
| New | +$8.58M |
|
|
CRWV
970
PUT
CoreWeave
CRWV
$48.5B
| $11M | 0.01% |
110,300
-56,000
| -34% | -$6.05M |
|
971
Gibraltar Industries
ROCK
$1.38B
| $11M | 0.01% |
243,403
+126,627
| +108% | +$4.96M |
|
972
Salesforce
CRM
$171B
| $11M | 0.01% |
70,046
+41,086
| +142% | +$7.22M |
|
973
CALL
Altria Group
MO
$110B
| $10.9M | 0.01% |
152,100
-28,200
| -16% | -$1.97M |
|
974
PUT
Morgan Stanley
MS
$336B
| $10.9M | 0.01% |
52,200
-33,000
| -39% | -$6.53M |
|
975
Klaviyo
KVYO
$5.22B
| $10.9M | 0.01% |
+718,899
| New | +$11.9M |
|
Similar funds
Dmitry Balyasny's Q2 2026 Portfolio in Review
As of Q2 2026, Dmitry Balyasny held 3,665 positions worth $80.2B, up 4% from $77.1B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Dmitry Balyasny withdrew a net $7.14B in Q2 2026, closing 734 positions and reducing 995 holdings. Its most notable exit was Hologic, an estimated $357M position sold in full.
By sector, the portfolio is most concentrated in Technology at 13% of assets, up from 9.7% a quarter earlier, followed by Industrials and Consumer Discretionary.
Against the trend, Dmitry Balyasny opened a new position in SpaceX worth $581M.
- Dmitry Balyasny's largest Q2 2026 buy was SpaceX: 3,397,642 shares worth $581M.
- Dmitry Balyasny added most to State Street SPDR S&P 500 ETF Trust in Q2 2026, an estimated $538M increase.
- Dmitry Balyasny's biggest Q2 2026 reduction was Meta Platforms (Facebook), cutting an estimated $326M.
- Dmitry Balyasny fully exited Hologic in Q2 2026, selling an estimated $357M.
- Dmitry Balyasny's ten largest holdings make up 14% of its $80.2B portfolio in Q2 2026.
- Dmitry Balyasny opened 834 new positions and closed 734 in Q2 2026.
- Dmitry Balyasny's portfolio value rose 4% quarter-over-quarter to $80.2B.
Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.